54
Participants
Start Date
April 6, 2022
Primary Completion Date
July 14, 2025
Study Completion Date
August 13, 2025
Nintedanib (Ofev®)
Nintedanib (Ofev®) soft capsules
Brussels - UNIV HUDERF, Brussels
Weill Cornell Medicine-New York-60569, New York
Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg
Tampere University Hospital, Tampere
Vanderbilt University Medical Center, Nashville
Hospital Virgen del Rocío, Seville
Azienda Ospedaliera Meyer, Florence
Clinical Research Institute S.C., Tlalnepantla
"General Hospital of Thessaloniki Ippokrateio", Thessaloniki
Children's Hospital Colorado, Aurora
Children's Hospital Los Angeles, Los Angeles
HOP Intercommunal, Créteil
Serviços Medicos Respirar Sul Fluminense, Barra Mansa
Hospital de Pediatria Prof. Dr. Juan P. Garrahan, CABA
Hospital de Niños Dr. Ricardo Gutierrez, CABA
Centro de Pesquisa Clinica do Instituto da Crianca - HCFMUSP, São Paulo
BC Children's Hospital, Vancouver
The Hospital for Sick Children, Toronto
Teaching Hospital Motol, Oncology Clinic, Prague
Osp. Pediatrico Bambin Gesù, Roma
Oslo Universitetssykehus HF, Rikshospitalet, Oslo
Independent Public Teaching Children's Hospital, Warsaw
ULS de São José, E.P.E. - Hospital Dona Estefânia, Lisbon
ULS de Santa Maria, E.P.E, Lisbon
Hospital Universitari Vall D Hebron, Barcelona
King's College Hospital, London
Lead Sponsor
Boehringer Ingelheim
INDUSTRY